Tag Archives: coronavirus vaccine

Coronavirus Vaccine: Moderna and Pfizer Final Test Results Imminent

Moderna should have enough data from its late-stage trial to know whether its coronavirus vaccine works in November, CEO Stephane Bancel said Thursday. The company could have enough data by October, but that’s unlikely, Bancel said during an interview on CNBC’s “Squawk Box.

If the infection rate in the country were to slow down in the next weeks, it could potentially be pushed out in a worst-case scenario in December,” he added.

Moderna is one of three drugmakers backed by the U.S. in late-stage testing for a potential vaccine. The other two are companies Pfizer and AstraZeneca.

Moderna‘s experimental vaccine contains genetic material called messenger RNA, or mRNA, which scientists hope provokes the immune system to fight the virus. In July, the company released early-stage data that showed its potential vaccine generated a promising immune response in a small group of patients.

Bancel’s comment came four days after the CEO of Pfizer said its vaccine could be distributed to Americans before the end of the year. CEO Albert Bourla told CBS’ “Face the Nation” that the company should have key data from its late-stage trial for the Food and Drug Administration by the end of October. If the FDA approves the vaccine, the company is prepared to distribute “hundreds of thousands of doses,” he said.

Source: https://www.cnbc.com/

Hundreds of Thousands Of People In China Should Have Been Vaccinated At Present

China in recent months has been injecting hundreds of thousands of people with three preliminary coronavirus vaccines that are being tested for safety and efficacy. While the world awaits a proven drug to fight the pandemic, at least three vaccine candidates have been given to front-line medical professionals, staff of state-owned companies, and government officials since July under an emergency use program approved by Beijing.

China National Biotec Group (CNBG), a subsidiary of state-owned Sinopharm, has administered two experimental vaccine candidates to around 350,000 people outside its clinical trials, CNBG chairman Yang Xiaoming said recently. The company also donated 200,000 doses of one of the candidate vaccines that is still undergoing clinical trials in Wuhan, where the pandemic was first reported.

Another drugmaker, Sinovac Biotech, has injected 90% of its employees and their family members, or about 3,000 people, Yin Weidong, the company’s CEO, said this month.

At present, tens of thousands of people in Beijing should have been vaccinated with Sinovac’s vaccine,” Yin told Chinese state media. Separately, Beijing also gave approval in June for members of the armed forces to receive an experimental vaccine developed by CanSino Biologics, a biopharmaceutical company that is backed by the military.

Under China’s law, vaccines developed for major public health emergencies can be deployed for urgent use if the National Medical Products Administration considers that the benefits of the treatment outweigh the risks.

Source: https://www.voanews.com/

Chinese Covid-19 Vaccine Ready For Public By November

Chinese manufacturers have been bullish about development, with companies Sinovac Biotech and Sinopharm even putting their vaccine candidates on display at a trade fair in Beijing this month. A China-developed coronavirus vaccine could be ready for the public as early as November, a Chinese official has told state television, as the global race to clear the final round of trials heats up.

Representatives of the firms told AFP that they hope their vaccines will be approved after phase 3 trials as early as year-end.

And on late Monday, the chief biosafety expert at the Chinese Centre for Disease Control told state broadcaster CCTV that a vaccine would be available to the general public “around November or December.”
https://medicalxpress.com/

Coronavirus: Russian vaccine shows signs of immune response

Russian scientists have published the first report on their coronavirus vaccine, saying early tests showed signs of an immune response.
The report published by medical journal The Lancet said every participant developed antibodies to fight the virus and had no serious side effects. Russia licensed the vaccine for local use in August, the first country to do so and before data had been published.

Experts say the trials were too small to prove effectiveness and safety. But Moscow has hailed the results as an answer to critics. Some Western experts have raised concerns about the speed of Russia’s work, suggesting that researchers might be cutting corners.

Last month, President Vladimir Putin said the vaccine had passed all the required checks and that one of his own daughters had been given it. Two trials of the vaccine, named Sputnik-V, were conducted between June and July, The Lancet paper said. Each involved 38 healthy volunteers who were given a dose of the vaccine and then a booster vaccine three weeks later.
The participants – aged between 18 and 60 – were monitored for 42 days and all of them developed antibodies within three weeks. Among the most common side effects were headaches and joint pain. The trials were open label and not randomised, meaning there was no placebo and the volunteers were aware they were receiving the vaccine.

https://www.bbc.com/

New Chinese Vaccine Lacks Of New Patients At Home To Test

China National Biotec Group (CNBG) has won approval to run a large-scale “Phase 3clinical trial  of its novel coronavirus vaccine candidate in the United Arab Emirates (UAE), the company said on Tuesday. China is seeking to trial potential vaccines overseas because of a lack of new patients at home.

Over a dozen experimental vaccines are being trialled around the world. None of them has yet successfully completed a late-stage “Phase 3test to determine efficacy in shielding healthy people from the virus, which has killed over 470,000 people around the world. Such trials involve thousands of participants and normally take place in countries where the virus is widespread, so that the vaccine can be observed in a real-life environment.

However, China, the origin of the global pandemic, reported fewer than 10 new local cases a day on average last month, and its researchers are now looking abroadCNBG announced the move in a Weibo social media post, without naming the vaccine to be tested in the UAE. Units of CNBG, an affiliate of the state-owned China National Pharmaceutical Group (Sinopharm), have developed two potential vaccines, which have together been given to over 2,000 people in previous tests in China.

Other Chinese companies seeking to trial vaccines overseas include Clover Biopharmaceuticals, whose shots have been given to participants in Australia in an early study, and Sinovac Biotech (SVA.O), which is expected to begin a Phase 3 trial in Brazil with 9,000 volunteers.

Source: https://www.reuters.com/

Moderna Coronavirus Vaccine Candidate Has 65% Chance Of Success

Morgan Stanley, which recently named Moderna Inc (NASDAQ: MRNA) as one of the likeliest candidates to succeed in the coronavirus vaccine race, reviewed the interim Phase 1 data released by the company Monday. The Moderna Analyst Matthew Harrison maintained an Overweight rating on Moderna shares and increased the price target from $37 to $90.
Moderna’s ability to scale coupled with promising early results positions it well to compete in the market, Harrison said in a Wednesday note. The analyst expects Moderna to sell about 1.5 billion doses of the vaccine during the pandemic period and 150 million annual doses during the endemic period.

Given the promising early results, we risk-adjust our estimates assuming a 65% probability of success, slightly higher than the ~56% of typical PhII vaccine candidates.”

Breaking down Morgan Stanley’s valuation model, Harrison said $23 of the firm’s price target increase is attributable to the coronavirus vaccine. $12 per share is assigned to year-end 2021 cash and lower dilution; $11 per share is attributed to the higher chance of success across the vaccine platform and $7 is for the increase in platform value, the analyst said. Morgan Stanley expects full Phase 1 data to be available by the time the Phase 3 study starts in July, and projects the Phase 2 data will be released in the fall of 2020.

Interim Phase 3 data is likely to be available as early as the end of the year, Harrison said.

Source: https://www.modernatx.com/
AND
https://finance.yahoo.com